Mirabegron

Indications

Megron ER tablet is used to relieve symptoms of overactive bladder (OAB) in adults, including urgency, frequent urination and urgency incontinence.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Mirabegron is the first medicine in its class, known as a beta-3 adrenoceptor agonist. It works through two complementary pathways: acting directly on the smooth muscle of the bladder wall, and acting through the sensory nerves that supply the bladder. By activating beta-3 adrenoceptors, it raises levels of cyclic adenosine monophosphate (cyclic AMP), which relaxes the detrusor (bladder wall) muscle during the filling/storage phase of the bladder's fill-void cycle. The net effect is an increase in the bladder's capacity to hold urine.

Pregnancy & Breastfeeding

There is only limited data on the use of mirabegron in pregnant women. Studies in animals have shown reproductive toxicity, so mirabegron is not recommended during pregnancy or for women who are planning to become pregnant.

In rodents, mirabegron is excreted in milk, so it is expected to pass into human breast milk too. No studies have looked at how mirabegron affects milk production in humans, whether it appears in breast milk, or what effect it has on a breastfed child. For that reason, mirabegron should not be given during breastfeeding.

In animals, mirabegron had no treatment-related effect on fertility. Its effect on fertility in humans has not been established.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: For adults, including elderly patients, the recommended starting dose is one Mirabegron 25 mg tablet taken once daily, with or without food. Depending on how well the individual patient responds and tolerates the medicine, the dose may be increased to one Mirabegron 50 mg tablet once daily. In patients with renal or hepatic impairment, those with severe renal impairment (ClCr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m2) or moderate hepatic impairment (Child Pugh Class B) should not receive more than 25 mg of Mirabegron once daily. Mirabegron has not been studied in patients with end stage renal disease (GFR below 15 mL/min/1.73 m2, or patients requiring haemodialysis) or severe hepatic impairment (Child Pugh Class C), so its use is not recommended in these patient groups. No dose adjustment is required based on gender. In the paediatric population, the safety and efficacy of Mirabegron in children under 18 years of age have not yet been established. The Mirabegron tablet should be taken once daily with liquid, swallowed whole, and should not be chewed, divided, or crushed.

Suggest a correction

Indications

Pharmacology

Pregnancy & Breastfeeding

Dosage Reference

Side Effects & Interactions

Side Effects

Key Interactions